Trials / Recruiting
RecruitingNCT04883905
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Conditions
Timeline
- Start date
- 2021-04-26
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
- First posted
- 2021-05-12
- Last updated
- 2026-02-17
Locations
30 sites across 10 countries: United States, Belgium, France, Germany, Italy, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT04883905. Inclusion in this directory is not an endorsement.